CLINICAL TRIALS PROFILE FOR SUMATRIPTAN

All Clinical Trials for SUMATRIPTAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00122278 ↗	Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines	Completed	Montefiore Medical Center	Phase 3	2005-07-01	Migraines are a specific type of headache that frequently recur and are very painful. Although there are many medications that are effective against migraines, none of these medications cure 100% of migraines. Another problem with migraines is that although many times they get better after intravenous (IV) treatment in the emergency room (ER), about 1/3 of the time migraines recur the next day. The purpose of this research project is to see if adding a medication called dexamethasone to standard ER therapy will help patients get better quicker and stay pain-free more often than if they receive placebo.
NCT00184587 ↗	Prophylactic Treatment of Episodic Cluster Headache	Completed	AstraZeneca	Phase 2	2005-03-01	The purpose of this study is to determine whether candesartan cilexetil are effective prophylactic treatment of episodic Cluster headache
NCT00184587 ↗	Prophylactic Treatment of Episodic Cluster Headache	Completed	Norwegian University of Science and Technology	Phase 2	2005-03-01	The purpose of this study is to determine whether candesartan cilexetil are effective prophylactic treatment of episodic Cluster headache
NCT00240617 ↗	Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks	Completed	GlaxoSmithKline	Phase 3	2005-10-01	The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
NCT00240630 ↗	Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks	Completed	GlaxoSmithKline	Phase 3	2005-10-01	The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.
NCT00274170 ↗	Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache	Unknown status	C.R.Darnall Army Medical Center	Phase 1/Phase 2	2006-01-01	: Headaches are a common complaint presenting to the emergency department (ED), accounting for 1-2% of all ED visits, with migraines as the second most common primary headache syndrome. Patients that ultimately present to the ED have failed outpatient therapy and exhibit severe and persistent symptoms. Treatment options have been traditionally with a parenteral opiod, generally Demerol. Unfortunately, patients with chronic painful conditions like migraines have been prone to dependency. In 1986, a nonopioid, compazine was noted serendipitously to relieve migraine headache pain. 1 Nonopioid regimens have evolved as standard therapy in the treatment of migrainne headache in the ED. Today, there are a number of nonopioid treatment options, but not without their own individual concerns. Ergotamine and dihydroergotamine are effective, but commonly cause nausea and vomiting. Sumatriptan is expensive has recurrence rate, is ineffective in about 20-30%, and is contra-indicated in patients with cardiac disease. Metoclopramide, a dopamine receptor antagonist, commonly used as an anti-emetic agent, has been widely studied for use with acute migraines. Its side effects include drowsiness and dystonic reactions. Compazine has been successfully used to treat migraine headaches for the past several decades, and has been accepted as standard treatment of headaches in the ED. 2 Its side effect profile includes extrapyramidal effects, dysphoria, drowsiness and akathisias. The ideal medication for treating headaches would have no addictive properties, few side effects, quick onset, be highly effective and have a low rate of recurrence. Somatostatin is known to have an inhibitory effect on a number of neuropetides, which have been implicated in migraine. Native somatostatin is an unstable compound and is broken down in minutes, but octreotide, a somatostatin analogue has a longer half life. Intravenous somatostatin has been shown to be as effective as ergotamine in the acute treatment of cluster headache. 3 The analgesic effect of octreotide with headaches associated with growth hormone secreting tumor has been established. 4 Five somatostatin receptors have been cloned with octreotide acting predominantely on sst2 and sst5. The distribution of sst2 within the central nervous system strongly suggests that this particular somatostatin receptor has a role in cranial nociception, being highly expressed in the trigeminal nucleus caudalis and periaqueductal grey. Kapicioglu et.al performed a double blind study comparing octreotide to placebo in treating migraine. They found there to be a significantly greater relief of pain with octreotide at 2 and 6 hours compared to placebo (76% vs 25%, p

Clinical Trial Conditions for SUMATRIPTAN

Condition Name

Condition Name for SUMATRIPTAN
Intervention	Trials
Migraine Disorders	30
Migraine	29
Healthy	12
Migraine Without Aura	9

Condition MeSH

Condition MeSH for SUMATRIPTAN
Intervention	Trials
Migraine Disorders	80
Headache	38
Migraine without Aura	9
Cluster Headache	7

Clinical Trial Locations for SUMATRIPTAN

Trials by Country

Trials by Country for SUMATRIPTAN
Location	Trials
United States	502
Denmark	16
China	5
Egypt	5
India	4

Trials by US State

Trials by US State for SUMATRIPTAN
Location	Trials
Florida	27
California	27
New York	26
Missouri	23
Michigan	23

Clinical Trial Progress for SUMATRIPTAN

Clinical Trial Phase

Clinical Trial Phase for SUMATRIPTAN
Clinical Trial Phase	Trials
PHASE3	1
PHASE1	1
Phase 4	15

Clinical Trial Status

Clinical Trial Status for SUMATRIPTAN
Clinical Trial Phase	Trials
Completed	93
Unknown status	9
RECRUITING	7

Clinical Trial Sponsors for SUMATRIPTAN

Sponsor Name

Sponsor Name for SUMATRIPTAN
Sponsor	Trials
GlaxoSmithKline	25
Danish Headache Center	12
NuPathe Inc.	8

Sponsor Type

Sponsor Type for SUMATRIPTAN
Sponsor	Trials
Industry	91
Other	75
U.S. Fed	1

Clinical Trials Update, Market Analysis, and Projection for Sumatriptan

Last updated: April 27, 2026

What is the current clinical and regulatory state for sumatriptan?

Sumatriptan is an established prescription acute treatment for migraine. Its development history is mature and the global commercial position is anchored in marketed products rather than ongoing late-stage innovation.

Clinical development profile

• Indication scope (commercially established): acute treatment of migraine attacks (with or without aura).
• Development pattern: post-approval work typically centers on formulation improvements, route-of-administration variants, and lifecycle management rather than new clinical efficacy proof.

Trial activity signal (what matters for investors)

For an already-approved small molecule with a long market history, value-relevant clinical updates usually fall into three buckets:

1. New dosage forms (nasal, subcutaneous, oral alternatives)
2. Bioequivalence and formulation stability programs
3. Safety updates and post-marketing studies tied to labeling maintenance

Actionable implication: absent a new patent-protected generation, near-term clinical trial headlines generally have limited direct impact on pricing power, revenue trajectory, or ownership of new market exclusivity.

Which sumatriptan products drive market access by route and formulation?

Market supply is distributed across multiple routes that map to acute-care workflows:

• Oral tablets
• Oral disintegrating or oral powder formats (where available)
• Nasal spray
• Subcutaneous injection
• Other localized formulations depending on region and brand portfolio

Actionable implication: projection models should treat sumatriptan as a category with route mix effects rather than as a single launch narrative.

---

How big is the sumatriptan market today, and what segments matter most?

A robust market model requires category sizing and route mix. In sumatriptan, segmentation typically follows:

• Geography (US, EU5, UK, Japan, rest of world)
• Patient access (brand vs generic penetration)
• Route of administration (oral dominates in most markets; injections and nasal carry higher per-dose value)

Market forces that shape demand

Key demand determinants for migraine acute therapy categories:

• Migraine prevalence and diagnosis rates
• Formulary coverage and payer step therapy
• Generic adoption timelines
• Switching by patient preference (rapid onset routes for severe attacks)
• Competing acute classes (CGRP antagonists and ditans) that shift share at the margin

Competitive context

Sumatriptan competes with:

• Triptans (class peers)
• New acute migraine agents (including CGRP receptor antagonists and ditans) that can reduce triptan share in higher-acuity segments

Actionable implication: projection should assume continued share pressure from newer acute agents, partially offset by sumatriptan’s breadth of coverage and clinician familiarity.

---

What does pricing and generic erosion imply for revenue projections?

Sumatriptan is widely genericized in many jurisdictions. Generic erosion typically drives:

• Lower net prices per dose
• Higher unit consumption only if patient access expands
• Route-level price compression with time, unless a route retains meaningful brand differentiation

Projection logic investors use

Revenue for an established genericized molecule usually tracks:

• Units (prescriptions or doses)
• Net price per dose (brand premium minus generic discounting)
• Mix (oral vs nasal vs injection)

Actionable implication: forecast sensitivity is dominated by net price decline and route mix shifts more than by incremental clinical trial outcomes.

---

What is the likely 5-year market trajectory for sumatriptan?

Based on typical small-molecule acute migraine trajectories after generic penetration, the base case is:

• Moderate volume stability or slow growth driven by baseline migraine population and formularies
• Declining or flat net revenue per dose
• Share dilution from newer acute products that offer alternative profiles for patients who do not respond to triptans or who seek faster relief

Base case (directional)

• Units: stable to slightly up
• Net revenue: flat to down
• Share: down versus newer acute classes, stable within triptans

Downside and upside framing (directional)

• Downside: faster uptake of CGRP/ditan competitors in managed care, stronger step-edits, and more aggressive price undercutting
• Upside: expanded access, improved route mix (nasal/injection retention for rapid onset), and slower-than-expected generic pricing pressure in some markets

Actionable implication: equity and partnership decisions should prioritize route-specific pricing resilience and payer coverage rather than expecting clinical breakthroughs to move category-level revenue.

---

How should investors underwrite sumatriptan exposure across ownership structures?

Brand portfolios vs generics

Revenue attribution depends on whether the holder benefits from:

• Legacy brand premiums in specific geographies
• Contract manufacturing and supply economics
• Dossier ownership and exclusive line extensions (if any)

IP and exclusivity reality check for sumatriptan

For a long-established molecule, incremental value typically comes from:

• Formulation IP (if protected in specific jurisdictions)
• Process improvements (limited market impact unless legally enforced)
• Orphan-like exclusivity is not a relevant model here
• New active ingredient protection does not apply because sumatriptan is the active ingredient

Actionable implication: sumatriptan is best underwritten as a cash-generating, lifecycle-managed product rather than as a growth platform.

---

What clinical signals should be monitored to impact future market share?

Because sumatriptan is not a late-stage pipeline driver, the only clinical signals likely to move category share are:

• Safety label changes that affect eligibility or payer policy
• Formulation switching that affects adherence and patient outcomes
• Regional regulatory updates impacting dosing routes and indications wording

Actionable implication: track regulator communications and label updates more than novel efficacy trial publications.

---

Key Takeaways

• Sumatriptan is a mature, genericized acute migraine therapy with clinical value dominated by access, formulation, and lifecycle changes rather than new breakthrough trials.
• Market outcomes are driven mainly by generic price erosion, route mix, and share pressure from newer acute migraine classes.
• A practical 5-year base case is stable units with flat-to-declining net revenue, with modest share dilution versus CGRP/ditan competitors.
• Investment underwriting should prioritize pricing resilience by route and geography, payer formulary position, and supply economics over pipeline-style clinical updates.

---

FAQs

1) What is sumatriptan used for?

Sumatriptan is used to treat acute migraine attacks, with use patterns shaped by route (oral, nasal, subcutaneous) and onset needs.

2) Does sumatriptan still have active clinical development?

Ongoing activity is generally lifecycle-focused, centered on formulations, dosing routes, and post-marketing/safety maintenance rather than new pivotal efficacy evidence.

3) How does generic competition affect sumatriptan revenue?

Generic penetration typically causes net price declines, so category revenue often depends on units and mix rather than pricing power.

4) What competes with sumatriptan in acute migraine?

Newer acute options include CGRP receptor antagonists and ditans, plus other triptans; newer classes can take share in specific patient segments.

5) What drives the 5-year outlook most?

The main drivers are net price trend, payers’ step therapy rules, route mix, and relative share shift from newer acute products.

---

References

[1] FDA. (n.d.). Label information for Imitrex (sumatriptan). U.S. Food and Drug Administration. https://www.fda.gov/
[2] EMA. (n.d.). EPARs for sumatriptan-containing products. European Medicines Agency. https://www.ema.europa.eu/
[3] DailyMed. (n.d.). Drug label: sumatriptan products (Imitrex and generics). U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
[4] NCBI Bookshelf. (n.d.). Migraine and triptans overview (therapeutic context). National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/
[5] IQVIA / industry market reports. (n.d.). Acute migraine market dynamics and class performance (category-level reporting).